Profile data is unavailable for this security.
About the company
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
- Revenue in USD (TTM)0.00
- Net income in USD-277.80m
- Incorporated2014
- Employees258.00
- LocationCogent Biosciences Inc275 Wyman Street, 3Rd FloorWALTHAM 02451United StatesUSA
- Phone+1 (617) 945-5576
- Websitehttps://www.cogentbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.46bn | 59.00 | -- | 12.95 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.50bn | 103.00 | -- | 11.85 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.51bn | 511.00 | -- | 16.28 | -- | 7.11 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.84bn | 196.00 | -- | 7.17 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.88bn | 113.00 | -- | 6.58 | -- | 2,243.32 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Celcuity Inc | 0.00 | -162.72m | 5.01bn | 87.00 | -- | 40.07 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Alkermes Plc | 1.48bn | 241.66m | 5.04bn | 2.05k | 21.12 | 2.75 | 18.47 | 3.42 | 1.43 | 1.43 | 8.74 | 10.99 | 0.6498 | 1.04 | 4.08 | 719,950.80 | 10.64 | 10.11 | 13.68 | 13.22 | 86.69 | 84.10 | 16.37 | 15.06 | 3.19 | -- | 0.00 | 0.00 | -5.25 | 7.28 | -35.06 | -- | -0.8671 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.65bn | 362.00 | -- | 5.72 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Protagonist Therapeutics Inc | 46.02m | -130.15m | 6.01bn | 132.00 | -- | 9.59 | -- | 130.68 | -2.04 | -2.04 | 0.7239 | 9.82 | 0.0651 | -- | 12.10 | 348,606.10 | -18.42 | -8.51 | -19.72 | -9.31 | -- | -- | -282.83 | -31.44 | -- | -- | 0.00 | -- | -89.41 | 9.96 | -147.29 | -- | 27.55 | -- |
| Cogent Biosciences Inc | 0.00 | -277.80m | 6.31bn | 258.00 | -- | 11.45 | -- | -- | -2.15 | -2.15 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -51.99 | -55.96 | -57.41 | -62.16 | -- | -- | -- | -- | -- | -- | 0.2594 | -- | -- | -- | -37.96 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.66bn | 25.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.67bn | 209.00 | -- | 16.42 | -- | 299.27 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.36bn | 238.00 | -- | 4.64 | -- | 187.60 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.57bn | 673.00 | -- | -- | -- | 85.94 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 7.96bn | 228.00 | -- | 6.35 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Cogent Biosciences Inc's reporting currency: US Dollar USD
50.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 21.43m | 14.10% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 10.56m | 6.95% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.35m | 6.80% |
| RTW Investments LPas of 31 Dec 2025 | 7.59m | 4.99% |
| Kynam Capital Management LPas of 31 Dec 2025 | 6.17m | 4.06% |
| Fairmount Funds Management LLCas of 22 Jan 2026 | 5.50m | 3.62% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.94m | 3.25% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 4.50m | 2.96% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.51m | 2.31% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 2.46m | 1.62% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
